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chemoattractants, while the CXC ELR2 chemokines
bind a different set of CXC receptors and are more active
on lymphocytes. While most of the chemokines belong
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Ludwig-Maximilians-University to the CC or CXC classes, two additional branches, C
and CX3C chemokines, have also been described (re-Schillerstrasse 42
80336, Munich viewed by Murphy et al., 2000; Rossi and Zlotnik, 2000).
Lymphotactin-a/XCL1 and lymphotactin-b/XCL2 are CGermany
†Division of Immunology and chemokines that share homology at their carboxyl end
with the CC chemokines but lack the first and thirdTransplantation Biology
Department of Pediatrics, CCSR 2105 cysteines in the four-cysteine motif (Murphy et al., 2000;
Rossi and Zlotnik, 2000). Fractalkine/CX3CL1, the onlyStanford University
Stanford, California 94305 CX3C chemokine described, has three intervening amino
acids between the first two cysteine residues. It is teth-
ered directly to the cell membrane via a mucin stalk and
combines the functions of both a chemokine and anIntroduction
adhesion molecule. Fractalkine/CX3CL1 can induce cell
adhesion and migration as either a membrane-tetheredThe emigration of leukocytes from the peripheral circula-
or shed-soluble ligand (Murphy et al., 2000; Rossi andtion into an allograft is an essential component of organ
Zlotnik, 2000).transplant rejection. Ischemic damage and surgical
Chemokines can be further classified according totrauma set the stage for early leukocyte infiltration and
function and regulation of expression (Murphy et al.,activation, leading in turn to the recruitment of additional
2000; Zlotnik and Yoshie, 2000). Some chemokines areeffector leukocytes and the propagation of damage to
important in the control of inflammatory processes,the graft. Productive alloreactivity in vivo also requires
while others are involved in normal trafficking of leuko-processes controlled within secondary lymphoid organs
cytes through primary and secondary lymphoid organs(Lakkis et al., 2000). The migration of dendritic cells
(Campbell and Butcher, 2000; Murphy et al., 2000; Rossifrom the allograft into secondary lymphoid tissue is of
and Zlotnik, 2000; Zlotnik and Yoshie, 2000). The “inflam-paramount importance to the rejection process (Lakkis
matory” chemokines are regulated by proinflammatoryet al., 2000). The biology of chemokines underlies both
stimuli and help orchestrate innate and adaptive immuneleukocyte recruitment and important aspects of the
responses. The second group contains those chemo-adaptive immune response.
kines involved in homeostatic activity important in lym-Chemokines were first characterized by their ability
phocyte and dendritic cell trafficking during immuneto induce migration of leukocytes (Segerer et al., 2000;
surveillance (Table 1). The homeostatic chemokines areZlotnik and Yoshie, 2000). This family of chemotactic
generally thought to be “constitutively” expressedcytokines has subsequently been shown to play impor-
(Campbell and Butcher, 2000; Murphy et al., 2000; Zlot-tant roles in the control of leukocyte recruitment, activa-
nik and Yoshie, 2000).tion, and effector function, as well as hematopoiesis,
the modulation of angiogenesis, and aspects of adaptive
immunity (Keane and Strieter, 1999; Campbell and
Chemokine ReceptorsButcher, 2000; Murphy et al., 2000; Rossi and Zlotnik,
The actions of chemokines are mediated through a large2000; Sallusto et al., 2000; Segerer et al., 2000). These
family of seven-transmembrane-spanning serpentinediverse biologic actions underlie many of the acute and
Gi/Go protein–coupled receptors that are sensitive tochronic processes that make up allograft dysfunction.
Pertussis toxin (Murphy et al., 2000; Rossi and Zlotnik,To date, 44 chemokines and 21 chemokine receptors
2000; Sallusto et al., 2000) (Figure 1). Each chemokinehave been described (Murphy et al., 2000; Rossi and
receptor has a distinct chemokine specificity and a re-Zlotnik, 2000; Segerer et al., 2000) (Tables 1 and 2).
stricted expression for subclasses of leukocytes (TableThe separation of this chemokine superfamily into four
2). Nevertheless, the ligand specificities of the receptorsbranches (C, CC, CXC, and CX3C) is based upon the
can overlap, as some chemokines bind to multiple re-position of the first two cysteine residues in a four-
ceptors, and some receptors can bind multiple chemo-cysteine motif in their primary amino acid sequence and
kines (Murphy et al., 2000; Segerer et al., 2000; Zlotnikwhether or not they are separated by additional amino
and Yoshie, 2000). Receptors can be specific and bindacids (designated as X). A subgroup of CXC chemokines
only one ligand, or they can share ligands from the samedisplays the additional E-L-R-CXC amino acid motif (glu-
general family. The Duffy antigen, also a chemokinetamic acid-leucine-arginine-cysteine-X-cysteine) (ELR1)
binding protein, can bind members of both the CXC and(Table 1). These chemokines generally act as neutrophil
CC chemokine subfamilies (Table 2) (Murphy et al., 2000;
Segerer et al., 2000; Zlotnik and Yoshie, 2000). In gen-
eral, the proinflammatory chemokine receptors tend to‡ To whom correspondence should be addressed (e-mail: nelson@
have more promiscuous ligand binding specificities,medpoli.med.uni-muenchen.de [P. J. N.], krensky@stanford.edu
[A. M. K.]). while the receptors involved in normal leukocyte traffick-
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Table 1. Chemokines: Names and Actions
CC -ELR- H/I Other Nomenclature
CCL1 NA I I-309, TCA3, P500
CCL2 NA I MCP-1, MCAF, (mouse; JE)
CCL3 NA I LD78a, LD78b, MIP-1a
CCL4 NA I Act-2, G-26, HC21, H400, MIP-1b, LAG-1, SISg, MAD-5
CCL5 NA I RANTES
CCL7 NA I MCP-3
CCL8 NA I MCP-2, HC14
CCL11 NA I eotaxin
CCL12 NA I (mouse) MCP-5
CCL13 NA I MCP-4, NCC-1, CKb10
CCL14 NA I HCC-1, HCC-3, NCC-2, CKb1, MCIF
CCL15 NA I HCC-2, NCC-3, MIP-5, Lkn-1, MIP-1d
CCL16 NA I NCC-4, LEC, HCC-4, LMC, LCC-1, CKb12
CCL17 NA H TARC
CCL18 NA H? DC-CK1, PARC, MIP-4, CKb7, DCCK1
CCL19 NA H ELC, MIP-3b, exodus-3, CKb11
CCL20 NA H MIP-3a, LARC, exodus-1, ST38, CKb4
CCL21 NA H SLC, 6Ckine, exodus-2, TCA4, CKb9
CCL22 NA H MDC, STCP-1, DC/B-CK
CCL23 NA I MIP-3, MPIF-1, CKb8
CCL24 NA I MPIF-2, CKb6, eotaxin-2
CCL25 NA H TECK, Ckb15
CCL26 NA I eotaxin-3, IMAC, MIP-4a, TSC-1
CCL27 NA H ALP, skinkine, ILC, ESkine, PESKY, CTAK
CCL28 NA H MEC, CCK1
CXC -ELR- H/I Other Nomenclature
CXCL1 ELR1 I GROa, MGSA-a, NAP-3, (mouse/rat; KC, MIP-2, CINC-2b)
CXCL2 ELR1 I GROb, MIP-2a, MGSA-b, CINC-2a
CXCL3 ELR1 I GROg, MIP-2b, CINC-2b
CXCL4 ELR2 I PF4
CXCL5 ELR1 I ENA-78
CXCL6 ELR1 I GCP-2
CXCL7 ELR1 I CTAPIII, NAP-2, LA-PF4, MDGF, LDGF, b-TG
CXCL8 ELR1 I IL-8, NAP-1
CXCL9 ELR2 I mig
CXCL10 ELR2 I IP-10
CXCL11 ELR2 I I-TAC
CXCL12 ELR2 H SDF-1a, SDF-1b, PBSF
CXCL13 ELR2 H BLC, BCA-1
CXCL14 ELR2 I BRAK, bolekine, MIP-2g, BMAC, KS1
CXCL15 ELR1 H lungkine
CXCL16 ELR? ? SR-Psox
C -ELR- H/I Other Nomenclature
XCL1 NA I Lymphotactin, SCM-1a, ATAC
XCL2 NA I SCM-1b
CX3C -ELR- H/I Other Nomenclature
CX3CL1 NA I Fractalkine, neurotactin
Chemokines (common and official names), the presence of ELR-CXC motifs, and homeostatic (H) versus inflammatory (I) designation, based
on chemokine expression and receptor specifity. NA, not applicable. For definitions of the various acronyms, see Murphy et al. (2000) (see
also http://cytokine.medic.kumamoto-u.ac.jp/ for detailed up-to-date information on the various chemokines).
ing have relatively few ligands. The nomenclature used 2000; Segerer et al., 2000). This brings about a transient
rise in intracellular calcium and subsequent activationto describe the individual chemokine receptors is based
upon the class of chemokine ligands that interacts with of protein kinase C. A series of protein kinases are then
involved in downstream signal transduction cascades,the receptor (i.e., C, CC, CXC, and CX3C receptors) (Mur-
phy et al., 2000; Rossi and Zlotnik, 2000). including serine/threonine kinases (e.g., members of the
MAP kinase cascade) and tyrosine protein kinases (Mur-Chemokine receptors generally undergo internaliza-
tion and phosphorylation following ligand binding. The phy et al., 2000; Segerer et al., 2000).
Chemokine regulation of leukocyte migration appearsbinding of a chemokine ligand to its receptor activates
Ga protein subunits. The subsequent Gi or Gq signal to occur in a complex milieu of chemotactic signals
where several receptors may be triggered simultane-transduction cascade leads to the activation of phos-
pholipase Ca1 and a2 and the generation of inositol ously or successively. Within this complex environment
of receptor cross-talk and desensitization, the migrating(1,4,5)-trisphosphate and diacylglycerol (Murphy et al.,
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Figure 1. Multimolecular Complex in Chemo-
kine Action
A multimolecular complex is generally in-
volved in chemokine action. For example, the
chemokine RANTES/CCL5 can be presented
by a glycosaminoglycan moiety on the endo-
thelial cell surface to a seven-transmem-
brane-spannning G protein–associated ser-
pentine receptor expressed on the surface of
immune cells.
leukocyte must distinguish a hierarchy of signals within modified receptor variants exist (Rodriguez-Frade et al.,
1999; Murphy et al., 2000; Nelson et al., 2001). It hasthe tissue to reach the site of inflammation (Foxman et
al., 1997; Hancock et al., 2000a; Segerer et al., 2000). been suggested that heterodimers of receptors could
add considerable flexibility to the overall functional sig-As a further complication of this already baroque biol-
ogy, at least some chemokine receptors form homo- nificance of receptor–ligand interactions by allowing a
different function for heterodimers relative to that foror heterodimers, and it appears that posttranslationally
Table 2. Chemokine Receptors, Chemokines Reported to Bind, and Cell Types Expressing the Receptor
Chemokine
Receptor Chemokine Receptor-Expressing Cell Type
CCR1 CCL3, CCL5, CCL7, CCL8, monocyte, dendritic cell (immature), T cell, neutro-
CCL13, CCL14, CCL15, CCL23 phil, eosinophil, mesangial cell, platelet
CCR2 CCL2, CCL7, CCL8, CCL13 monocyte, dendritic cell (immature), basophil, T cell,
natural killer cell, endothelial cell, fibroblast
CCR3 CCL5, CCL7, CCL8, CCL11, eosinophil, basophil, Th2 T cell, dendritic cell, plate-
CCL13, CCL14, CCL15, lets
CCL24, CCL26
CCR4 CCL17, CCL22 dendritic cell (immature), basophil, Th2 T cell, plate-
lets
CCR5 CCL3, CCL4, CCL5, CCL8, Th1 T cell, dendritic cell (immature, mature), mono-
CCL11, CCL13, CCL14 cyte, natural killer cell, thymocyte
CCR6 CCL20 dendritic cell (immature), T cells, B cells
CCR7 CCL19, CCL21 dendritic cell (mature), T cell, B cell
CCR8 CCL1, CCL16 monocyte, B cell, T cell, thymocyte
CCR9 CCL25 T cell, thymocyte
CCR10 CCL27, CCL28 T cell, melanocytes, dermal endothelium, dermal
fibroblast, Langerhans cells
CCR11 CCL19, CCL21, CCL25 astrocyte
CXCR1 CXCL5, CXCL6, CXCL8 neutrophil, monocyte, astrocytes, endothelium
CXCR2 CXCL1, CXCL2, CXCL3, CXCL5, neutrophil, monocyte, eosinophil, endothelium
CXCL7, CXCL8
CXCR3 CXCL9, CXCL10, CXCL11 Th1 T cell, B cell, mesangial cell, smooth muscle
cell
CXCR4 CXCL12 T cell, dendritic cell (immature, mature), monocyte,
B cell, neutrophil, platelet, astrocyte
CXCR5 CXCL13 T cell, B cell, astrocyte
CXCR6 CXCL16
XCR1 XCL1, XCL2 T cell
CX3CR1 CX3CL1 natural killer cell, T cell, astrocyte
Duffy CXCL8, CCL1, CCL5, CXCL1, red blood cells, endothelium
CXCL7
D6 CCL2, CCL4, CCL5, CCL8, B cell
CCL13, CCL14, CCL15
Chemokines, chemokine receptors, their ligand specificity, and tissue distribution (Murphy et al., 2000; Nelson et al., 2001) (see http://
crf.medic.kumamoto-u.ac.jp for recent updates on chemokine/receptor information).
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Figure 2. Multistep Process in Generation of
Inflammatory Infiltrate in Transplant Re-
jection
A series of chemokine gradients are thought
to be required for the recruitment of inflam-
matory cells from the bloodstream into sites
of inflammation.
homodimers or through altered sensitivity to chemokine cyte integrins and endothelial immunoglobulins remain
in an unactivated state (Butcher and Picker, 1996;stimulation. Posttranslational modification of receptors
could also yield a cell type- or activation-specific form Campbell and Butcher, 2000). Specific chemokines ei-
ther generated by activated endothelial cells or releasedof chemokine receptor (Murphy et al., 2000; Nelson et
al., 2001). following platelet activation bind to the surface of “acti-
vated” endothelium. Endothelium is an early discrimina-
tor of leukocyte infiltration, as different endothelial cellsChemokines in Transplantation
Transplantation research is important not only for its show altered ability to present individual chemokines
(Grone et al., 1999; von Hundelshausen et al., 2001).clinical relevance but also as a tool to identify and dis-
sect more general aspects of immune regulation. One Chemokines presented by the endothelium are thus ide-
ally situated to direct and sort leukocytes through theof the benefits of animal models of transplantation is
that, by adjusting the MHC disparity between the graft allograft parenchyma by triggering the activation of the
leukocyte-expressed integrins, resulting in shear-resis-and host, one can regulate the severity of the rejection
process. In addition, both acute and chronic inflamma- tant, firm adhesion of the leukocyte to the endothelial
surface (Butcher and Picker, 1996; Weber et al., 1999;tory events can be studied, and the disease process is
initiated at the time of transplantation, thus allowing Segerer et al., 2000; von Hundelshausen et al., 2001;
Weber et al., 2001). Additional chemokines appear toprecise kinetic monitoring of events.
then influence subsequent events associated with leu-
kocyte emigration, including spreading, diapedesis, andChemokines and Leukocyte Recruitment
into Allografts extravasation (Weber et al., 1999) (Figure 2).
The release of microparticles from eukaryotic cells isFollowing transplantation, ischemic injury enhanced by
reperfusion of the allograft is associated with microvas- a well-recognized phenomenon (Mack et al., 2000). It
was recently shown that microparticles containingcular stress and trafficking of leukocytes into microvas-
cular spaces (Ambrosio and Tritto, 1999). The multistep CCR5 can transfer the receptor from peripheral blood
mononuclear cells to endothelial cells during transendo-process of effector leukocyte recruitment into the allo-
graft involves a series of interactions between molecules thelial migration. Thus, intercellular transfer of chemo-
kine receptors by microparticles might have broad impli-expressed on the leukocyte and the endothelial surface
(Butcher and Picker, 1996; Campbell and Butcher, 2000; cations for intercellular communication (Mack et al.,
2000).Segerer et al., 2000) (Figure 2).
Stressed cells (for example, within kidney grafts) pro- A specialized role of apparently redundant receptors
in early stages of leukocyte trafficking was recently dem-duce increased oxygen and nitric oxide radicals (Calo
et al., 2000). This in turn leads to the production and onstrated (Weber et al., 2001). Monocytes and Th1-like
T cells can express both CCR1 and CCR5, which in turnrelease of inflammatory mediators such as platelet-acti-
vating factor and tumor necrosis factor and enhances share ligand specificities, including RANTES/CCL5. The
role of these receptors in the selective recruitment ofthe expression of adhesion molecules that mediate leu-
kocyte rolling and firm adhesion to the endothelium monocytes and Th1 T cells was tested in an in vitro
system where firm arrest under flow conditions was trig-(Butcher and Picker, 1996; Calo et al., 2000; Segerer et
al., 2000). During selectin-mediated rolling, the leuko- gered by RANTES/CCL5 immobilized to endothelium.
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Figure 3. Potential Sites for Therapeutic In-
tervention in Chemokine Action
(1) Proinflammatory cytokine induction in stro-
mal cells (TNF or IL-1 inhibitors; not shown),
(2) early T cell activation (classical immuno-
suppressives like cyclosporin, tacrilomus, or
anti-CD3), (3) gene expression (corticoste-
roids, novel transactivators), (4) translation
and secretion (select cytostatics), (5) binding
to endothelium (heparin), (6) serpentine re-
ceptors (CCR1 or CXCR3 receptor blockade),
and/or (7) G proteins and downstream signal
(select kinase inhibitors).
Using selective receptor antagonists, it was found that chemokine function is the cleavage of MCP-3/CCL7 by
matrix metalloproteinase gelatinase A (MMP2) (McQuib-RANTES-induced arrest of these cells was predomi-
nantly mediated by CCR1, while CCR5 mainly contrib- ban et al., 2000). The cleavage product binds to CCR1,
CCR2, and CCR3 and acts as a potent antagonist thatuted to leukocyte spreading in shear flow. Nevertheless,
both CCR1 and CCR5 could support transendothelial suppresses inflammation. This suggests that matrix
metalloproteinases are both effectors and regulators ofchemotaxis toward RANTES/CCL5. Thus, not all chemo-
kine receptors expressed by effector leukocytes are the inflammatory response (McQuibban et al., 2000) and
that proteolytic processing may provide an additionalnecessarily involved in direct recruitment from the pe-
ripheral circulation. Understanding the functional role of level of control for differential cell recruitment and for
the regulation of target cell specificity. Thus, the inter-individual chemokine receptors in leukocyte adhesion,
emigration, and effector cell activation will be beneficial pretation of in situ hybridization or immunohistochemi-
cal data may be difficult, as the presence of a givenin the development and application of specific chemo-
kine receptor antagonists for transplant rejection (Fig- chemokine does not necessarily prove that it is acting
to specifically recruit leukocytes. Through proteolyticure 3).
Chemokines have additional biological activities that processing, for example, a chemokine could be acting
as a selective antagonist.are also relevant to diverse processes that contribute
to allograft rejection. The ELR1 CXC chemokines IL-8/
CXCL8, ENA-78/CXCL5, and GRO-a/CXCL1 act as angi- Dendritic Cells, Chemokines, Chemokine Receptors,
and T Cell Responsesogenic agents, while the ELR2 chemokines PF4/CXCL4,
IP-10/CXCL10, Mig/CXCL9, and SDF-1/CXCL12 are an- Dendritic cells appear to play dual roles in the immune
response to allografts, both as promoters of rejectiongiostatic factors (Keane and Strieter, 1999; Hancock et
al., 2000a; Murphy et al., 2000). Thus, for example, during and mediators of tolerance (Sallusto et al., 2000). Den-
dritic cells derived from the allograft can act as potentchronic rejection, the expression of chemokines could
influence the microvasculature within the allograft. inducers of an alloresponse. In response to signals pro-
duced during inflammation, dendritic cells undergo mat-In addition, leukocytes extravasate by partially digest-
ing and loosening the basement membrane. Chemo- uration leading to migration to secondary lymphoid or-
gans such as spleen, lymph nodes, and mucosalkines induce T cell and monocyte secretion of the matrix
metalloproteinases required for migration through base- lymphoid tissues where they present their complement
of MHC-associated antigens. Secondary lymphoid tis-ment membranes (Segerer et al., 2000). This phenome-
non could promote the degradation of matrix and the sues provide the environment for dendritic cells to selec-
tively activate naive T and B lymphocytes. The impor-perturbation of tissue homeostasis and thus enhance
tissue damage in acute and chronic allograft rejection. tance of this process in allograft rejection was recently
demonstrated by Lakkis et al., who showed that cardiacThe functional activity of chemokines can also be
modified through posttranslational proteolytic pro- allografts could be accepted indefinitely in recipient
mice that lack secondary lymphoid tissue, suggestingcessing (Van Damme et al., 1999). Dipeptidyl peptidase
IV enzymes, such as CD26, can cleave chemokines that that the alloimmune response to a vascularized organ
transplant requires trafficking of dendritic cells to sec-share a conserved NH2-X-Pro (where X is any amino
acid) sequence at their amino terminus. The enzymes ondary nodes (Lakkis et al., 2000).
Immature dendritic cells express inflammatory che-cleave after the Pro residue, resulting in a two amino
acid deletion. This modification can alter the receptor mokine receptors CCR1, CCR2, CCR5, and CXCR1. This
group of receptors helps account for the ability of thesespecificity of the chemokine. The chemokine substrates
for these enzymes include MCP-2/CCL2, IP-10/CXCL10, cells to migrate into inflamed tissues (Murphy et al.,
2000; Sallusto et al., 2000; Sozzani et al., 2000). DuringRANTES/CCL5, and eotaxin/CCL11 (Van Damme et al.,
1999). An additional example of protease regulation of maturation, these receptors decrease in expression, and
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the chemokine receptors that help direct the mature CXCR3, CCR1, and CCR7 (reviewed in Nelson et al.,
2001). In addition, endothelial cells, epithelial cells,dendritic cell to the lymphoid environments, CCR4,
CXCR4, and CCR7, increase in expression (Murphy et microglial cells, and neurons can express chemokine
receptors (Keane and Strieter, 1999; Murphy et al., 2000;al., 2000; Sallusto et al., 2000; Sozzani et al., 2000).
In this regard, CCR7 appears to play a pivotal role in Rossi and Zlotnik, 2000). Although the overall function
of chemokine receptor expression by nonhematopoieticmigration of dendritic cells from inflamed tissue to sec-
ondary lymphoid tissue (Forster et al., 1999). In contrast, cells remains incompletely understood, it may play a role
in angiogenesis, atherosclerosis, and wound healing. ItCCR6 appears to be a mucosa-specific regulator of hu-
moral immunity and lymphocyte homeostasis (Cook et is of interest that chemokines and their receptors are
expressed differentially during renal ontogeny (CXCR3,al., 2000).
Within the secondary lymphoid organs, chemokines IP-10/CXCL10, CXCR4, SDF-1/CXCL12, Fractalkine/
CX3CL1, CX3CR1, CCR7, and SLC/CCL21) (reviewed bymay also act to position antigen-loaded dendritic cells
and antigen-specific T cells for efficient cell–cell com- Nelson et al., 2001). As genes that are expressed differ-
entially during ontogeny often play a role in tissue regen-munication. In a reciprocal manner to dendritic cells,
activation of naive T cells results in decreased expres- eration, these embryonal chemokine/chemokine recep-
tor patterns may reflect the role of these factors in renalsion of chemokine receptors such as CXCR4 and CCR7
and increased expression of inflammatory receptors, injury and repair, a potentially important issue when
considering chronic blockade of chemokine receptorsincluding CCR5, CCR3, CXCR3, and CCR8 (Murphy et
al., 2000; Sallusto et al., 2000; Sozzani et al., 2000). This as a means of therapeutic intervention (see below).
switch in receptor expression facilitates the migration
of the activated T cells to sites of inflammation. Subse- Regulation of Chemokine Expression
quent selective tissue homing to specific anatomic sites Inflammatory chemokines are generally found in two
has also been correlated with the expression of unique clusters on human chromosomes 4 (CXC) and 17 (CC)
chemokine receptor patterns (Campbell and Butcher, (Murphy et al., 2000; Segerer et al., 2000). Due to geno-
2000). mic clustering of these genes, it has been suggested that
Chemokine receptor expression is also associated there may be coordinate regulation at both the individual
with the events surrounding the outcome of an adaptive and regional levels analogous to that seen for other gene
immune response (Murphy et al., 2000; Sallusto et al., family clusters (Murphy et al., 2000; Segerer et al., 2000;
2000; Sozzani et al., 2000). Th1-like and Th2-like re- Nelson et al., 2001). It is now thought that, rather than
sponses represent the extremes of a spectrum for a acting as single molecules, inflammatory chemokines
potential immune response. The Th1 subtype produces may be functionally coregulated in groups that may in
strong cellular immune responses that are stimulated turn activate common chemokine receptors (Murphy et
by pathogens that invade and inhabit cells and result in al., 2000; Segerer et al., 2000). This apparent redundancy
an activation of cytotoxic T lymphocytes and delayed- reflects a complexity that could provide a high degree
type hypersensitivity. Allograft rejection is mediated in of flexibility in vivo and may explain why chemokine
part by Th1-like processes. The Th2-like subtypes evoke and chemokine receptor knockouts often do not display
strong antibody responses. In addition, the Th2-derived pronounced phenotypes (Segerer et al., 2000; Nelson
cytokines can suppress the proinflammatory reactions et al., 2001).
induced by the Th1 cytokines (Murphy et al., 2000; Sal- Inflammatory chemokines are regulated at multiple
lusto et al., 2000; Sozzani et al., 2000). Thus, the Th1/Th2 levels, involving transcriptional, posttranscriptional,
balance can either elicit immunity or reinforce tolerance. translational, and posttranslational events (Segerer et
Differential expression of chemokine receptors has al., 2000). IL-1b, IFN-g, or TNF-a alone or in combination
been linked to the development of a Th1- or Th2-type induce many of the proinflammatory chemokines (Seg-
immune response. While the patterns are not absolute, erer et al., 2000). CXC chemokines, Mig/CXCL9 and IP-
Th1-like cells appear to preferentially express the che- 10/CXCL10, were initially identified on the basis of their
mokine receptors CXCR3 and CCR5, while Th2 cells selective induction by IFN-g (Murphy et al., 2000).
generally display CCR4 and CCR8, with a subpopulation RANTES/CCL5 is of particular interest as an example
that also expresses CCR3 (Murphy et al., 2000; Sallusto of this specialized regulation. Although it, like many
et al., 2000; Sozzani et al., 2000). Thus, the chemokine other CC chemokines, is expressed as an immediate
receptors expressed by different populations of T cells early gene in fibroblasts, epithelial cells, and endothelial
may be linked to tissue infiltration of Th1 versus Th2 cells cells within minutes of stimulation by proinflammatory
and/or the functional response of receptor-expressing cytokines like IL-1b and TNF-a, it is expressed “late,”
cells, thus determining the ultimate outcome of an im- 3–5 days after activation, in T lymphocytes (Song et
mune response (Hancock et al., 2000a; Sallusto et al., al., 2000). This late expression kinetic appears to help
2000; Segerer et al., 2000; Sozzani et al., 2000; Nelson amplify the immune response in both time and space.
et al., 2001). Inflammatory cells first enter the site of inflammation in
response to the early chemokines, but only T cells with
receptors for specific antigen(s) will be activated, prolif-Chemokine and Chemokine Receptor Expression
by Nonlymphoid Tissues erate, and release additional RANTES days later. This
unusual expression makes RANTES a novel target forThe biology of chemokines has become more compli-
cated with the demonstration that nonhematopoietic tis- immunotherapy (Song et al., 2000) (Figure 3).
RANTES expression in T lymphocytes is regulatedsues also express functional chemokine receptors. For
example, human mesangial cells express functional transcriptionally by RANTES Factor of Late-Activated T
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Lymphocytes (RFLAT)-1 (Kruppel-like Factor 13, KLF- CCR5, CCR2, CXCR4, and Duffy, have subsequently
been demonstrated in biopsy samples from human renal13) and other transactivators (Song et al., 1999).
RFLAT-1 itself is translationally regulated (Song et al., allografts undergoing rejection (reviewed by Segerer et
al., 2000; Nelson et al., 2001).2000). Its 59 untranslated region regulates translation of
RFLAT-1 in response to factors that affect eIF4e. Thus, Infiltration by CCR5-expressing leukocytes occurs
during both acute and chronic phases of human renalthe original concept of “late T cell activation” and a
developmental switch in expression of transcription fac- allograft rejection (reviewed by Segerer et al., 2000; Nel-
son et al., 2001). The distribution of the CCR5-positivetors (Ortiz et al., 1997) may be replaced by a new concept
of a translational–transcriptional rheostat that regulates infiltrate in areas of endothelialitis, tubulitis, and intersti-
tial infiltrates during cellular rejection mirrors the generalchemokine expression in a dynamic way in a terminally
differentiated T lymphocyte (Song et al., 2000). For ex- expression of RANTES/CCL5 in these tissues (Segerer
et al., 2000; Nelson et al., 2001). The functional impor-ample, growth factors and/or cellular stress may in-
crease eIF4E, which in turn leads to an increase in tance of CCR5-positive leukocytes in human renal allo-
graft survival was dramatically demonstrated in a largeRFLAT-1 expression. RFLAT-1 binds the RANTES pro-
moter, modulating expression in a more responsive time cohort of patients genetically lacking CCR5. Approxi-
mately 1% of individuals of northern European heritageframe than previously recognized.
For “inflammatory” chemokines, signaling pathways are homozygous for CCR5D32, a null allele of CCR5
(Murphy et al., 2000; Rossi and Zlotnik, 2000). Due to acan be different for each stimulus and transcription fac-
tor, may vary from cell type to cell type, and can be 32 base pair deletion within the coding region of the
gene, these individuals lack functional receptor. Thesefurther complicated by “cross-talk” between various
pathways. This complex control system may permit fine individuals do not show an obvious phenotype in general
but appear to be highly resistant to productive HIV infec-tuning and integration of the multiple signals required
for a tissue-specific response. Such signal transduction tion (Murphy et al., 2000; Rossi and Zlotnik, 2000; Seg-
erer et al., 2000). Fischereder and Luckow studied thepathways are potential targets for therapeutic interven-
tion (Figure 3). prevalence of the CCR5D32 genotype in over 1200 renal
transplant recipients. Twenty-one patients within this
group were identified as homozygous for the null allele.Kidney Transplantation
Of 22 renal transplants performed in these 21 patients,Rat models of renal transplantation have allowed an
only one showed a loss of function during followup.analysis of the expression and functional role of select
Based upon these observations, it appears that thechemokines and chemokine receptors in acute and
absence of CCR5 results in a significantly prolongedchronic allograft rejection (reviewed by Segerer et al.,
allograft half-life, as compared to the heterozygous or2000; Nelson et al., 2001). RANTES/CCL5, MCP-1/CCL2,
wild-type allele (60 versus 17 years) (Fischereder et al.,and lymphotactin/XCL1 expression increases during re-
2001). These are the strongest data to date supportingjection. RANTES/CCL5 mRNA expression is localized to
an important role of chemokines, especially CCR5-posi-infiltrating leukocytes, tubular epithelial cells, and endo-
tive leukocytes, in human renal transplant nephropathythelial cells by in situ hybridization. Lymphotactin/XCL1
(Segerer et al., 2000; Nelson et al., 2001). It is intriguingis expressed in infiltrating leukocytes. In studies of trans-
that, with the explosion of interest in the developmentplantation of Fisher kidneys into Lewis rats, treatment
of novel CCR5 antagonists for treatment of HIV infection,with a RANTES/CCL5-receptor antagonist, Met-RANTES,
strategies designed to block viral fusion may have thesignificantly reduced recruitment of inflammatory cells
added benefit of moderating transplant rejection.and vascular and tubular damage in acute renal allograft
The monitoring of chemokines in urine may providerejection (Grone et al., 1999). In a high-responder model
a dynamic picture of the inflammatory state of the kid-(Brown Norway kidney into Lewis rat), the combination
ney. At present, data have been reported for the urinaryof Met-RANTES and low-dose cyclosporin A markedly
excretion of MCP-1/CCL2 and IL-8/CXCL8 during renalreduced damage to vessels and tubules and interstitial
allograft rejection (reviewed by Nelson et al., 2001).rejection (Grone et al., 1999).
While in the past similar efforts have not been informa-In humans, we first showed that RANTES/CCL5 pro-
tive, the urinary excretion of chemokines may reflect thetein could be identified in 17 of 20 biopsies from human
intrarenal inflammatory cell infiltrate and in this regardkidneys undergoing acute cellular rejection (Pattison et
may be of prognostic value as a measure of continuedal., 1994). RANTES/CCL5 mRNA was expressed by infil-
intrarenal inflammation.trating mononuclear cells and renal tubular epithelial
cells. Interestingly, RANTES/CCL5 protein was also
prominently localized to the endothelial surface of peri- Heart Transplantation
Targeted disruption of chemokine receptor genes intubular capillaries, although the endothelium was largely
negative for RANTES mRNA based on in situ hybridiza- mice has implicated chemokines in cardiac transplant
rejection (Gao et al., 2000; Hancock et al., 2000a, 2000b).tion. This finding suggested that the protein was depos-
ited on the endothelium by activated platelets, and, so Mice lacking CCR1 (2/2) have prolonged cardiac allo-
graft survival. Allografts across a class II mismatch werepositioned, it could enhance recruitment of monocytes
and T cells into the graft (Pattison et al., 1994; von Hun- permanently accepted by CCR12/2 recipients, and class
I- and class II–mismatched cardiac allografts were re-delshausen et al., 2001). Increased expression of che-
mokines, ENA-78/CXCL5, IL-8/CXCL8, MIP-1a/CCL3, jected more slowly than controls. Levels of cyclosporin
A with marginal effects in CCR11/1 mice resulted in per-MIP-1b/CCL4, MCP-1CCL2, IP-10/CXCL10, lymphotac-
tin/XCL1, and corresponding chemokine receptors, manent allograft acceptance in CCR12/2 recipients, with
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no sign of chronic rejection 50–200 days after trans- Watarai et al., 2000). IP-10/CXCL10 and Mig/CXCL9
plantation (Gao et al., 2000). The efficacy of CCR1 recep- were expressed in allografts 3 days before rejection was
tor blockade was tested in a rat heterotopic heart trans- complete, suggesting a role for these chemokines in
plant model using a specific small molecule antagonist, recruiting primed T cells into the allograft. Treatment of
BX 471. Analogous to the results with CCR12/2 mice, recipients with rabbit antiserum to Mig/CXCL9 but not to
treatment of rats with BX 471 and a subtherapeutic dose IP-10/CXCL10 delayed rejection of allografts 3–4 days,
of cyclosporin A was more effective in prolonging graft suggesting that Mig/CXCL9 mediates optimal recruit-
survival than in animals treated with either cyclosporin ment of T cell allografts during rejection (Koga et al.,
or BX 471 alone, thus showing a species-independent 1999; Watarai et al., 2000).
effect of a CCR1 blockade (Horuk et al., 2001). An increase in RANTES/CCL5 in bronchoalveolar la-
During acute cardiac allograft rejection, ligands for vage fluid was observed in patients undergoing lung
CXCR3 (IP-10/CXCL10, Mig/CXCL9, and I-TAC/CXCL11) transplant rejection compared with healthy lung trans-
are increased in expression. This is accompanied by infil- plant recipients (Belperio et al., 2000). An increase in
tration of CXCR3-expressing activated T cells. CXCR3 RANTES expression is also found in rat lung allografts
appears to play a key role in T cell activation, recruit- and correlates with recruitment of mononuclear cells
ment, and allograft destruction. Mice treated with anti- expressing CCR1 and CCR5 (Belperio et al., 2000). In
CXCR3 monoclonal antibody show prolonged allograft vivo neutralization of RANTES/CCL5, using anti-RANTES
survival. Mice deficient for CXCR3 (2/2) are highly resis- antibody, decreased mononuclear cell infiltration and
tant to acute allograft rejection and, when treated with reduced acute lung allograft rejection (Belperio et al.,
a transient, subtherapeutic dose of cyclosporin A, main- 2000). Patients with bronchiolitis obliterans, a manifes-
tained their allografts permanently, without evidence of tation of chronic lung transplant rejection, have in-
chronic rejection (Hancock et al., 2000a, 2000b). creased IL-8/CXCL8 in bronchoalveolar lavage fluid (Els-
The role of fractalkine/CX3CL1 and its receptor, sner et al., 2000; Hancock et al., 2000a). Bronchial
CX3CR1, was recently studied in murine models of heart epithelial cells are thought to be the source of IL-8/
allograft rejection (MHC-mismatched H-2d hearts into CXCL8, which in turn may mediate airway inflammation
H-2b mice) (Robinson et al., 2000). Factalkine/CX3CL1 and fibroproliferation in the pathogenesis of this most
expression was upregulated early on vascular tissues important long-term complication after lung trans-
and endothelium in rejecting allografts. At later stages plantation.
of rejection, increased expression was found around Enhanced expression of the chemokine CINC mRNA
vessels and on cardiac myocytes. In in vitro flow assays and prominent accumulation of neutrophils are charac-
across murine endothelium, treatment with either anti- teristic features of the immune response during acute
fractalkine- or anti-CX3CR1-blocking antibody signifi- rejection of liver transplants (Hancock et al., 2000a).
cantly inhibited peripheral blood mononuclear cell bind- Immunostaining in rat hepatic allografts during acute
ing to activated endothelium, suggesting that a large rejection revealed that CINC is expressed in the portal
proportion of leukocyte binding to murine endothelium areas by infiltrating mononuclear cells and neutrophils
occurs via the fractalkine/CX3CL1 and CX3CR1 adhesion (Yamaguchi et al., 1997). Serum CINC concentration in-
receptors (Robinson et al., 2000). Finally, the treatment creased significantly at a constant rate over time follow-
of transplanted animals with blocking anti-CX3CR1 anti- ing transplantation (Yamaguchi et al., 1997). Hepatic
body significantly prolonged allograft survival from 7 6 1 allografts treated with FK506 or isografts showed much
to 49 6 30 days, suggesting a critical role for fractalkine/ lower levels of CINC mRNA and less neutrophil infiltra-
CX3CL1 in the pathogenesis of acute rejection (Robinson tion compared with untreated allografts (Yamaguchi et
et al., 2000). al., 1997).
Chronic heart allograft dysfunction in humans is char-
Chemokines may also play an important role in tissue
acterized by graft atherosclerosis following transplanta-
regeneration after liver injury. After acetaminophen-
tion. RANTES/CCL5 is expressed by infiltrating neointi-
induced hepatotoxicity in mice, liver regeneration wasmal lymphocytes and macrophages in arterioles and
facilitated by the exogenous addition of ELR-containingvenules adjacent to the wall of the coronary artery and
CXC chemokines, MIP-2/CXCL2, ENA-78/CXCL5, or IL-in myofibroblasts within the neointima (von Hundels-
8/CXCL8. Intravenous administration of ELR-CXC che-hausen et al., 2001). In this regard, circulating platelets
mokines after liver damage significantly reduced histo-and the chemokine RANTES may contribute to interac-
logical and biochemical markers of hepatic injury (Hoga-tion and activation of monocytes and endothelium,
boam et al., 1999). These observations demonstrate thatthereby playing an important role in the pathogenesis
ELR-CXC chemokines may be novel hepatic regenera-of inflammatory and atherosclerotic disease (von Hun-
tive factors that may have prolonged therapeutic effectsdelshausen et al., 2001). It was recently demonstrated
in damaged liver.that deposition of RANTES by platelets could trigger
shear-resistant monocyte arrest on inflamed or athero-
Conclusionssclerotic endothelium (von Hundelshausen et al., 2001).
Chemokines are pivotal mediators in allograft rejectionTherefore, delivery of RANTES by platelets may contrib-
by virtue of their activity as regulators of leukocyteute to the rapid atherosclerosis seen in heart trans-
movement, adhesion, and effector function. Becauseplantation.
the regulation of effector cell infiltration is complex, it
is difficult to dissect the relative role of each chemokineSkin, Lung, and Liver Transplantation
in the inflammatory processes leading to allograft rejec-CXC and CC chemokine expression has been studied
in skin allograft rejection in mouse (Koga et al., 1999; tion, especially since many chemokines and chemokine
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(1999). Met-RANTES reduces vascular and tubular damage duringreceptors are seemingly redundant. Nevertheless, it is
acute renal transplant rejection: blocking monocyte arrest and re-clear from knockout and inhibitor experiments that spe-
cruitment. FASEB J. 13, 1371–1383.cific chemokine and/or chemokine receptor blockades
Hancock, W.W., Gao, W., Faia, K.L., and Csizmadia, V. (2000a).may influence various aspects of the rejection process.
Chemokines and their receptors in allograft rejection. Curr. Opin.
Therefore, therapeutic interventions aimed at chemo- Immunol. 12, 511–516.
kines and/or their receptors may prove useful in treat-
Hancock, W.W., Lu, B., Gao, W., Csizmadia, V., Faia, K., King, J.A.,
ment of transplant rejection and/or induction of immuno- Smiley, S.T., Ling, M., Gerard, N.P., and Gerard, C. (2000b). Require-
logic tolerance. Therapeutic effects will likely differ, ment of the chemokine receptor CXCR3 for acute allograft rejection.
depending upon the stage of rejection and the other J. Exp. Med. 192, 1515–1520.
therapeutics administered. The marked enhancement Hogaboam, C.M., Simpson, K.J., Chensue, S.W., Steinhauser, M.L.,
Lukacs, N.W., Gauldie, J., Strieter, R.M., and Kunkel, S.L. (1999).of long-term kidney transplant survival in patients homo-
Macrophage inflammatory protein-2 gene therapy attenuates ade-zygous for a CCR5 null allele is very encouraging for
novirus- and acetaminophen-mediated hepatic injury. Gene Ther.future therapies directed at CCR5-positive mononuclear
6, 573–584.
cells. Results with CCR1, CXCR3, and CX3CR1 block-
Horuk, R., Clayberger, C., Krensky, A.M., Wang, Z., Grone, H.J.,ades are also remarkable. Clearly, antagonists for che-
Weber, C., Weber, K.S., Nelson, P.J., May, K., Rosser, M., et al.
mokines and their receptors have the potential to be- (2001). A non-peptide functional antagonist of the CCR1 chemokine
come important therapeutics in treatment of acute and receptor is effective in rat heart transplant rejection. J. Biol. Chem.
chronic allograft rejection. 276, 4199–4204.
The authors apologize to all colleagues whose work Keane, M.P., and Strieter, R.M. (1999). The role of CXC chemokines
in the regulation of angiogenesis. Chem. Immunol. 72, 86–101.could not be cited in this review due to space limitations.
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